Back to top
more

Halozyme Therapeutics (HALO)

(Delayed Data from NSDQ)

$62.32 USD

62.32
5,459,277

+1.51 (2.48%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $62.05 -0.27 (-0.43%) 5:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Bristol-Myers (BMY) Reports Positive Data on Leukemia Drug

by Zacks Equity Research

Bristol-Myers Squibb Company (BMY) announced positive data from an ongoing phase II study on leukemia drug Sprycel in addition to a chemotherapy regimen modelled on a Berlin-Frankfurt-Munster high-risk backbone for two years.

    Zacks Equity Research

    Options Traders Expect Huge Moves in Halozyme Therapeutics (HALO) Stock

    by Zacks Equity Research

    Investors in Halozyme Therapeutics (HALO) need to pay close attention to the stock based on moves in the options market lately.

      Zacks Equity Research

      Implied Volatility Surging for Halozyme Therapeutics (HALO) Stock Options

      by Zacks Equity Research

      Surging implied volatility makes Halozyme Therapeutics (HALO) stock lucrative to the option traders.

        Zacks Equity Research

        Should You Buy Halozyme Therapeutics (HALO) Ahead of Earnings?

        by Zacks Equity Research

        Halozyme Therapeutics (HALO) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

          Zacks Equity Research

          Can Halozyme (HALO) Run Higher on Strong Earnings Estimate Revisions?

          by Zacks Equity Research

          Halozyme Therapeutics (HALO) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision.

            Zacks Equity Research

            Bristol-Myers (BMY) Collaborates With Halozyme for ENHANZE

            by Zacks Equity Research

            Bristol-Myers Squibb Company (BMY) enters into a collaboration and license agreement with Halozyme Therapeutics, Inc. (HALO).

              Zacks Equity Research

              Strength Seen in Halozyme Therapeutics (HALO): Stock Soars 21.2%

              by Zacks Equity Research

              Halozyme Therapeutics (HALO) was a big mover last session, as the company saw its shares rise more than 21% on the day amid huge volumes.

                Zacks Equity Research

                Roche's (RHHBY) Combination Cancer Remedy Wins FDA Approval

                by Zacks Equity Research

                Roche (RHHBY) announced that the FDA has granted approval to the subcutaneous injection of its marketed lymphoma drug MabThera/Rituxan as Rituxan Hycela for the treatment of adults with different types of blood cancers.

                  Zacks Equity Research

                  Why Halozyme Therapeutics (HALO) Might Surprise This Earnings Season

                  by Zacks Equity Research

                  Halozyme Therapeutics (HALO) could be an interesting stock for investors ahead of earnings, as it has a positive ESP and a favorable Zacks Rank.

                    Zacks Equity Research

                    Halozyme Therapeutics (HALO) in Focus: Stock Up 6.4%

                    by Zacks Equity Research

                    Halozyme Therapeutics, Inc. (HALO) saw its shares rise above 6% in the last trading session.

                      Zacks Equity Research

                      Can the Rally in Halozyme (HALO) Shares Continue?

                      by Zacks Equity Research

                      Halozyme Therapeutics, Inc. (HALO) has been on the move lately as the stock has risen by 15.1% in the past four weeks, and it is currently trading well above its 20-Day SMA.

                        Zacks Equity Research

                        Halozyme Therapeutics (HALO) Worth a Look: Stock Up 18%

                        by Zacks Equity Research

                        Halozyme Therapeutics, Inc. (HALO) shares rose almost 18% in the last trading session.

                          Zacks Equity Research

                          Halozyme (HALO) Up on Positive Phase II Data on PEGPH20

                          by Zacks Equity Research

                          Halozyme (HALO) announced top-line data from the combined analysis from its phase II HALO 202 study on PEGPH20.